Cargando…

The Ultra-Potent and Selective TLR8 Agonist VTX-294 Activates Human Newborn and Adult Leukocytes

BACKGROUND: Newborns display distinct immune responses that contribute to susceptibility to infection and reduced vaccine responses. Toll-like receptor (TLR) agonists may serve as vaccine adjuvants, when given individually or in combination, but responses of neonatal leukocytes to many TLR agonists...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dowling, David J., Tan, Zhen, Prokopowicz, Zofia M., Palmer, Christine D., Matthews, Maura-Ann H., Dietsch, Gregory N., Hershberg, Robert M., Levy, Ofer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3587566/ https://www.ncbi.nlm.nih.gov/pubmed/23483986 http://dx.doi.org/10.1371/journal.pone.0058164

Ejemplares similares

TLR8 agonist VTX-2337 enhances NKG2D-mediated cytotoxicity of NK cells
por: Lu, Hailing, et al.
Publicado: (2013)

Comparison of immune modulation by TLR8 agonist vtx-2337 (motolimod) in cancer patients and healthy volunteers
por: Dietsch, Greg, et al.
Publicado: (2014)

VTX‐1463, a novel TLR‐8 agonist, attenuates nasal congestion after ragweed challenge in sensitized beagle dogs
por: Royer, Christopher M., et al.
Publicado: (2015)

Coordinated Activation of Toll-Like Receptor8 (TLR8) and NLRP3 by the TLR8 Agonist, VTX-2337, Ignites Tumoricidal Natural Killer Cell Activity
por: Dietsch, Gregory N., et al.
Publicado: (2016)

Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Ferris, Robert L, et al.
Publicado: (2014)

A novel TLR-8 agonist attenuates nasal symptoms/congestion in both dog and human allergen challenge studies
por: Barrett, Edward G, et al.
Publicado: (2013)

The Imidazoquinoline Toll-Like Receptor-7/8 Agonist Hybrid-2 Potently Induces Cytokine Production by Human Newborn and Adult Leukocytes
por: Ganapathi, Lakshmi, et al.
Publicado: (2015)

Motolimod, a selective TLR8 agonist induces apoptosis in monocytic myeloid-derived suppressor cells (M-MDSC)
por: Rutnam, Zina J, et al.
Publicado: (2015)

The anti-tumor effects of cetuximab in combination with VTX-2337 are T cell dependent
por: Cheng, Yinwen, et al.
Publicado: (2021)

Vuelo 294
por: Mendiola, Víctor Manuel, 1954-
Publicado: (1997)

The TLR5 Agonist Flagellin Shapes Phenotypical and Functional Activation of Lung Mucosal Antigen Presenting Cells in Neonatal Mice
por: Sharma, Pankaj, et al.
Publicado: (2020)

Potent Adjuvanticity of a Pure TLR7-Agonistic Imidazoquinoline Dendrimer
por: Shukla, Nikunj M., et al.
Publicado: (2012)

Health Tract, No. 294: Marriage and Longevity
Publicado: (1867)

Whole genome sequence comparison of vtx2-converting phages from Enteroaggregative Haemorrhagic Escherichia coli strains
por: Grande, Laura, et al.
Publicado: (2014)

Design and Structural Requirements of the Potent and Safe TLR-9 Agonistic Immunomodulator MGN1703
por: Schmidt, Manuel, et al.
Publicado: (2015)

An efficient and scalable synthesis of potent TLR2 agonistic PAM(2)CSK(4)
por: Kaur, Arshpreet, et al.
Publicado: (2018)

Covalently Conjugated NOD2/TLR7 Agonists Are Potent and Versatile Immune Potentiators
por: Guzelj, Samo, et al.
Publicado: (2022)

Mushroom poisoning: retrospective analysis of 294 cases
por: Eren, Sevki Hakan, et al.
Publicado: (2010)

Induction of Potent Antigen-specific Cytotoxic T Cell Response by PLGA-nanoparticles Containing Antigen and TLR Agonist
por: Lee, Young-Ran, et al.
Publicado: (2013)

Pentoxifylline, dexamethasone and azithromycin demonstrate distinct age-dependent and synergistic inhibition of TLR- and inflammasome-mediated cytokine production in human newborn and adult blood in vitro
por: Speer, Esther M., et al.
Publicado: (2018)

TLR agonists induce sustained IgG to hemagglutinin stem and modulate T cells following newborn vaccination
por: Clemens, Elene A., et al.
Publicado: (2022)

VTX‐1 Liquid Biopsy System for Fully‐Automated and Label‐Free Isolation of Circulating Tumor Cells with Automated Enumeration by BioView Platform
por: Sollier‐Christen, Elodie, et al.
Publicado: (2018)

Red Hat RHCE 8 (EX294) Cert Guide
por: van Vugt, Sander
Publicado: (2020)

Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms
por: Andıç, Neslihan, et al.
Publicado: (2016)

SAT-294 A Case of Turner Syndrome with Ambiguous Genitalia
por: Rodriguez Barreto, Ana Maria, et al.
Publicado: (2019)

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon
por: Krarup, Astrid Raaby, et al.
Publicado: (2017)

New chimeric TLR7/NOD2 agonist is a potent adjuvant to induce mucosal immune responses
por: Gutjahr, Alice, et al.
Publicado: (2020)

Targeting TLR9 agonists to secondary lymphoid organs induces potent immune responses against HBV infection
por: Ushach, Irina, et al.
Publicado: (2022)

Lipid A Mimetics Based on Unnatural Disaccharide Scaffold as Potent TLR4 Agonists for Prospective Immunotherapeutics and Adjuvants
por: Strobl, Sebastian, et al.
Publicado: (2022)

Investigation of reactions at a momentum of 2.94 GeV/c
por: Barmin, V V, et al.
Publicado: (1971)

Global Reconstruction of Naturalized River Flows at 2.94 Million Reaches
por: Lin, Peirong, et al.
Publicado: (2019)

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines
por: Van Hoeven, Neal, et al.
Publicado: (2017)

Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment
por: Smith, Anton A. A., et al.
Publicado: (2020)

Design and Immunological Evaluation of a Hybrid Peptide as a Potent TLR2 Agonist by Structure-Based Virtual Screening
por: Zhang, Lulu, et al.
Publicado: (2021)

PPARD +294C overrepresentation in general and long-lived population in China Bama longevity area and unique relationships between PPARD +294T/C polymorphism and serum lipid profiles
por: Luo, Chen-Yuan, et al.
Publicado: (2015)

Development of a TLR7/8 agonist adjuvant formulation to overcome early life hyporesponsiveness to DTaP vaccination
por: Dowling, David J., et al.
Publicado: (2022)

Deoxyguanosine is a TLR7 agonist
por: Davenne, Tamara, et al.
Publicado: (2019)

NOD2 Agonist Promotes the Production of Inflammatory Cytokines in VSMC in Synergy with TLR2 and TLR4 Agonists
por: Sun, Jinghua, et al.
Publicado: (2012)

Constitutive and agonist stimulated ATP secretion in leukocytes
por: Campwala, Hinnah, et al.
Publicado: (2013)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
por: Chettab, Kamel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0ofmfseg6ablsrb8e0t6kk7l3r